Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval

The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of... This Viewpoint describes the implications of US Food and Drug Administration changes to postmarketing requirements. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval

Loading next page...
 
/lp/american-medical-association/the-oncologic-drugs-advisory-committee-votes-of-april-2021-CYrgFCmgSr

References (3)

Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2021.3046
Publisher site
See Article on Publisher Site

Abstract

This Viewpoint describes the implications of US Food and Drug Administration changes to postmarketing requirements.

Journal

JAMA OncologyAmerican Medical Association

Published: Nov 8, 2021

There are no references for this article.